Burjeel Holdings Partners In Groundbreaking Space Research On Diabetes Management For Astronauts

An upcoming space mission aims to determine if astronauts with diabetes can join future spaceflights. The Ax-4 mission, launching in May, will send a four-member international team to the International Space Station (ISS) for up to 14 days. They will conduct microgravity research and technology demonstrations. A key experiment, SUITE RIDE, involves UAE-based Burjeel Holdings and could transform space exploration for those with chronic medical conditions.

The Ax-4 crew includes Commander Peggy Whitson from the United States, Mission Pilot Shubhanshu Shukla from India, Mission Specialist Sławosz Uznański-Wiśniewski from ESA/Poland, and Mission Specialist Tibor Kapu from Hungary. Whitson expressed excitement about the study's potential impact on future human spaceflight missions for individuals with diabetes and other chronic conditions.

The study's main goal is to test medical capabilities that enhance diabetes monitoring and management in microgravity. It aims to demonstrate accurate blood glucose monitoring, data transmission, and insulin viability aboard the ISS. Techniques include collecting glucometer readings, calibrating continuous glucose monitors (CGM), and sharing data with ground-based medical teams.

Burjeel Holdings will supply medical technologies for the experiment and lead post-spaceflight testing and analysis. Dr. Mohammad Fityan, CMO of Burjeel Medical City, highlighted the importance of studying glucose metabolism in space for insights into insulin sensitivity and metabolic adaptation.

This research has implications beyond space exploration. Insights gained could improve healthcare delivery on Earth, especially in remote or extreme environments. The technology used in orbit might enable remote monitoring and treatment of oil rig workers at sea or adventurers in harsh conditions.

Studying biological processes in microgravity offers unique opportunities to understand diseases like Alzheimer's, Parkinson's, and cancer. The absence of gravity changes cellular behaviour, providing deeper insights into these conditions. Previous space research has already advanced knowledge of protein crystallisation and cellular ageing.

Significance of Collaboration

Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, emphasised the collaboration's significance: "Burjeel Holdings is proud to collaborate on this groundbreaking study aboard Ax-4." He noted that findings could benefit future astronauts and lead to advancements in patient care on Earth.

Whitson also commented on the UAE’s focus on innovation: "To all the young scientists, healthcare professionals, and aspiring astronauts in the UAE, your curiosity and dedication are the driving forces behind the future of space exploration and medical innovation."

The Ax-4 mission represents a significant step forward in integrating individuals with chronic conditions into space missions while potentially transforming healthcare practices on Earth.

With inputs from WAM